2024
Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Akiska Y, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender V, Castelo-Soccio L, Cotsarelis G, Craiglow B, Desai N, Doche I, Duque-Estrada B, Elston D, Goh C, Goldberg L, Grimalt R, Jabbari A, Jolliffe V, King B, LaSenna C, Lenzy Y, Lester J, Lortkipanidze N, Sicco K, McMichael A, Meah N, Mesinkovska N, Miteva M, Mostaghimi A, Ovcharenko Y, Piliang M, Piraccini B, Rakowska A, Salkey K, Schmidt A, Shapiro J, Sibbald C, Sinclair R, Suchonwanit P, Taylor S, Tosti A, Vañó-Galván S, Wall D, Fu J. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology 2024, 161 PMID: 39565602, DOI: 10.1001/jamadermatol.2024.4593.Peer-Reviewed Original ResearchLow-dose oral minoxidilOral minoxidilExpert consensus statementTopical minoxidilHair lossPediatric patientsConsensus statementModified Delphi processDelphi consensus processEfficacy of topical minoxidilResults of small studiesInternational expert consensus statementsTreating pediatric patientsAdverse effect profileLong-term safetyOff-label useSpecialty consultationOff-label prescribingDelphi processSurvey roundsEvidence-based dataConsensus processExpert panelSublingual minoxidilThird roundAchievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s459. DOI: 10.25251/skin.8.supp.459.Peer-Reviewed Original ResearchPP-NRSPatient Oriented Eczema MeasurePhase 3 trialAtopic dermatitisWeek 8Eczema Area and Severity Index scorePeak Pruritus Numerical Rating ScaleBody surface area involvementPruritus Numerical Rating ScaleInvestigator's Global AssessmentNumerical rating scaleSurface area involvementSeverity index scoreSleep disturbanceAnalyzed post hocSleep improvementImprovement of sleepTapinarof creamEvaluate sleep disturbancesSuperior efficacySleep disturbance scoresArea involvementTapinarofItchingGlobal assessmentACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. ACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS. Annals Of Allergy Asthma & Immunology 2024, 133: s9. DOI: 10.1016/j.anai.2024.08.055.Peer-Reviewed Original ResearchPatient Oriented Eczema MeasurePP-NRSAtopic dermatitisWeek 8Sleep disturbancePeak Pruritus Numerical Rating ScalePruritus Numerical Rating ScaleNumerical rating scaleAnalyzed post hocStatistically significant improvementEvaluate sleep disturbancesRating ScaleSleep improvementTapinarofWeek 1Itch reductionScore improvementTreatment groupsBaseline scoresItchingWeeksPost-hocSleepPatientsOutcomesPublisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 3193-3193. PMID: 39404927, PMCID: PMC11557806, DOI: 10.1007/s13555-024-01265-2.Peer-Reviewed Original ResearchBH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
O’Connor C, Asfour L, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Meah N, Ohyama M, Ovcharenko J, Primez R, Piraccini B, Rudnicka L, Corralo D, Shapiro J, Sinclair R, Smith B, Starace M, Galvan S, Wang K, York K, McDonald I, Wall D. BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists. British Journal Of Dermatology 2024, 191: i74-i75. DOI: 10.1093/bjd/ljae090.151.Peer-Reviewed Original ResearchLiver function testsFunction testsHIV testingHepatitis BLipid testingAlopecia areataSeverity of Alopecia ToolScreening bloodHair disordersRenal function testsRisk of cardiovascular diseaseJanus kinase inhibitorsDermatology Life Quality IndexJanus kinaseBritish Association of DermatologistsLife Quality IndexLaboratory testsHair loss disorderSystemic therapyThyroid testsIdentification of comorbiditiesImmune-mediatedRenal functionThyroid diseaseAssociation of DermatologistsImprovement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 1959-1968. PMID: 38904749, PMCID: PMC11265044, DOI: 10.1007/s13555-024-01208-x.Peer-Reviewed Original ResearchSymptoms of anxietyQuality of lifeDomain scoresHealth-related quality of lifeMeasures of quality of lifeMeasures of HRQoLHealth-related qualityBaricitinib 2 mgSALT scoreBaricitinib 4 mgPsychosocial distressAssociated with improvementsHair regrowthAA scaleMethodsThis post hoc analysisHRQoLDose of baricitinibInterquartile rangePhase III trialsResultsIn totalSevere alopecia areataPost hoc analysisDisease associated with high ratesDepressionScoresThe Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease durationIn‐person validation of the Ichthyosis Scoring System
Echeandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.Peer-Reviewed Original ResearchInterrater intraclass correlation coefficientsIntrarater reliabilityIn-personIntraclass correlation coefficientIn-person evaluationContent validityInterrater reliabilityHeterogeneous group of skin disordersGroup of skin disordersIntraraterMedical professionalsInterrater agreementErythema evaluationIchthyosis subtypesPhotographic evaluationErythema scoreInterraterErythemaQuantify severitySkin disordersClinical utilityIchthyosisScoring systemHeterogeneous groupCorrelation coefficient
2023
Efficacité dans les sous-groupes liée aux caractéristiques de la maladie de patients atteints de pelade dans les études BRAVE-AA1 et BRAVE-AA2
Mayo T, Taylor S, Ito T, Vañó-Galván S, Ball S, Lu N, Chiasserini C, Chen Y, Craiglow B, Leveque C. Efficacité dans les sous-groupes liée aux caractéristiques de la maladie de patients atteints de pelade dans les études BRAVE-AA1 et BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a336. DOI: 10.1016/j.fander.2023.09.579.Peer-Reviewed Original ResearchImprovement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. JEADV Clinical Practice 2023, 3: 242-248. DOI: 10.1002/jvc2.269.Peer-Reviewed Original ResearchSevere alopecia areataSymptoms of anxietyHealth-related qualityAlopecia areataWeek 36Hair regrowthAutoimmune hair loss disorderPsychological burdenBackground Alopecia areataProportion of patientsPhase 3 trialSelective Janus kinase 1JAK-2 inhibitorHair loss disorderBaricitinib 2Nonresponder imputationMethods PatientsHADS scoresMore patientsLarge trialsHospital AnxietyDepression ScaleAA symptomsPsychosocial distressAnalysis of covarianceWhen to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini B, Craiglow B, Sinclair R, Chen Y, Wu W, Ding Y, Somani N, Dutronc Y. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal Of Dermatology 2023, 189: 666-673. PMID: 37708254, DOI: 10.1093/bjd/ljad253.Peer-Reviewed Original ResearchSevere alopecia areataBaricitinib-treated patientsPhase III trialsAlopecia areataResponder subgroupBaricitinib 4Hair regrowthIII trialsGrowth mixture modellingTreatment expectationsLate respondersEarly respondersBaseline disease characteristicsTreatment of adultsSALT scoreWeek 52Baseline characteristicsClinical outcomesDisease characteristicsTreatment allocationHair lossPatientsResponse subgroupsRespondersSubgroupsClinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinib44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Mayo T, Taylor S, Ito T, Galván S, Ball S, Lu N, Chiasserinio C, Chen Y, Craiglow B. 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2. Journal Of The American Academy Of Dermatology 2023, 89: ab42. DOI: 10.1016/j.jaad.2023.07.173.Peer-Reviewed Original Research41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
Shapiro J, Ko J, Egeberg A, Somani N, Jedynak J, Torisu-Itakura H, Yu G, Lu N, Craiglow B. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: ab127. DOI: 10.1016/j.jaad.2023.07.511.Peer-Reviewed Original Research41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Ding Y, Chen Y, Mostaghimi A. 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials. Journal Of The American Academy Of Dermatology 2023, 89: ab55. DOI: 10.1016/j.jaad.2023.07.224.Peer-Reviewed Original ResearchJanus kinase inhibitors for alopecia areata
King B, Craiglow B. Janus kinase inhibitors for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: s29-s32. PMID: 37591562, DOI: 10.1016/j.jaad.2023.05.049.Peer-Reviewed Original ResearchScalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. Journal Of Dermatological Treatment 2023, 34: 2227299. PMID: 37381691, DOI: 10.1080/09546634.2023.2227299.Peer-Reviewed Original ResearchConceptsSevere alopecia areataHealth-related qualityHair regrowthAlopecia areataMinimal regrowthBaseline Hospital AnxietyProportion of patientsPhase 3 trialDepression Scale scoresGreater improvementBaricitinib 2Daily placeboMore patientsWeek 36Hospital AnxietyTreatment allocationSkindex-16PatientsScale scoreScore changePsychological symptomsPsychological burdenAreataTrialsThe Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata
Mesinkovska N, Craiglow B, Ball S, Morrow P, Smith S, Pierce E, Shapiro J. The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata. Dermatology And Therapy 2023, 13: 1503-1515. PMID: 37289409, PMCID: PMC10307747, DOI: 10.1007/s13555-023-00941-z.Peer-Reviewed Original ResearchPsychological impactEmotional burdenNegative psychological impactGreater psychological impactPoor QoLPsychosocial impactAA symptomsSocial consequencesIllness impactParticipantsIllness characteristicsAnalysis of varianceNational Alopecia Areata FoundationConclusionsThese resultsStigmaQuality of lifeSeverity subgroupsAnxietyOutcome measuresPhysical impactScalp hair lossDepressionQoLAlopecia areataCross-sectional studyScalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials. SKIN The Journal Of Cutaneous Medicine 2023, 7: s186. DOI: 10.25251/skin.7.supp.186.Peer-Reviewed Original Research
2022
502 The genomic and phenotypic landscape of ichthyosis: An analysis of 1000 kindreds
Sun Q, Marukian N, Cheraghlou S, Paller A, Larralde M, Bercovitch L, Levinsohn J, Ren I, Hu R, Zhou J, Zaki T, Fan R, Tian C, Saraceni C, Nelson-Williams C, Loring E, Craiglow B, Milstone L, Lifton R, Boyden L, Choate K. 502 The genomic and phenotypic landscape of ichthyosis: An analysis of 1000 kindreds. Journal Of Investigative Dermatology 2022, 142: s85. DOI: 10.1016/j.jid.2022.05.511.Peer-Reviewed Original Research